Understanding treatments for gout.

Gout is one of the most readily manageable of the rheumatic diseases. This article reviews basic pathways in purine metabolism, uric acid handling, and the pathogenic mechanism of clinical gout, as well as the areas in those pathways amenable to intervention. Attention is also given to associated comorbidities, such as hyperuricemia and obesity, hypertension, hyperinsulinemia, and coronary artery disease. The significance of lifestyle modifications, such as weight loss and alcohol reduction, is discussed as an important adjunct to pharmacotherapy in gout. Current and investigational agents used in gout management are also reviewed. Finally, treatment recommendations for acute and chronic gout are suggested.

[1]  H. Schumacher,et al.  Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? , 2005, The American journal of medicine.

[2]  C. Sharpe.  A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. , 1984, Canadian Medical Association journal.

[3]  Gerald D. Groff,et al.  Systemic steroid therapy for acute gout: a clinical trial and review of the literature. , 1990, Seminars in arthritis and rheumatism.

[4]  Y. Inada,et al.  Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. , 1981, Enzyme.

[5]  Bullock Pw,et al.  Intermittent control of hyperuricemia in the treatment of gout. , 1989 .

[6]  C. Torrance,et al.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. , 1992, The New England journal of medicine.

[7]  A. Tykarski.  Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. , 1991, Nephron.

[8]  M. Becker,et al.  Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. , 2004, The Journal of rheumatology.

[9]  M. Liang,et al.  Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. , 2000, The Journal of rheumatology.

[10]  S. Goldman.  Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies , 2003, Expert review of anticancer therapy.

[11]  J. Bomalaski,et al.  Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. , 2002, The Journal of rheumatology.

[12]  F. Messerli,et al.  Serum uric acid in essential hypertension: an indicator of renal vascular involvement. , 1980, Annals of internal medicine.

[13]  H. Simmonds,et al.  Beer drinking and its effect on uric acid. , 1984, British journal of rheumatology.

[14]  J. T. ter Maaten,et al.  Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. , 1997, Clinical science.

[15]  K. Hande,et al.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.

[16]  C. Weinberg,et al.  Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. , 1991, Annals of internal medicine.

[17]  C. Schumann,et al.  Current aspects of colchicine therapy -- classical indications and new therapeutic uses. , 2001, European journal of medical research.

[18]  T. B. Griffin,et al.  Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. , 1993, European journal of pharmacology.

[19]  R. Terkeltaub,et al.  Gout: on the brink of novel therapeutic options for an ancient disease. , 2004, Arthritis and rheumatism.

[20]  L. Siegel,et al.  Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. , 1994, The Journal of rheumatology.

[21]  D. Lloyd,et al.  The prevalence and prophylaxis of gout in England. , 1995, Journal of clinical epidemiology.

[22]  P. Shekelle,et al.  Management of Gout , 2016 .

[23]  A. Fam.  Gout in the Elderly , 1998, Drugs & aging.

[24]  P. Chong,et al.  Rasburicase for the Treatment and Prevention of Hyperuricemia , 2003, The Annals of pharmacotherapy.

[25]  R. Wortmann.  Recent advances in the management of gout and hyperuricemia , 2005, Current opinion in rheumatology.

[26]  H. Schumacher,et al.  Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. , 2005, Arthritis and rheumatism.

[27]  R. Bonnel,et al.  Deaths associated with inappropriate intravenous colchicine administration. , 2002, The Journal of emergency medicine.

[28]  R. Glynn,et al.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. , 1987, The American journal of medicine.

[29]  M. Lipkowitz,et al.  Uric acid transport , 2003, Current opinion in nephrology and hypertension.

[30]  A. Fam.  Gout, diet, and the insulin resistance syndrome. , 2002, The Journal of rheumatology.

[31]  S. Robins,et al.  The effects of alcoholic beverages on urate metabolism in gout sufferers. , 1995, British journal of rheumatology.

[32]  B. Joffe,et al.  Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study , 2000, Annals of the rheumatic diseases.

[33]  W. Currie.  Prevalence and incidence of the diagnosis of gout in Great Britain. , 1979, Annals of the rheumatic diseases.

[34]  G. Vincent.  [Treatment of chronic gout]. , 1970, Journal des sciences medicales de Lille.

[35]  F. Epstein,et al.  The relationship of serum uric acid to risk factors in coronary heart disease. , 1968, The American journal of medicine.

[36]  L. B. Sorensen,et al.  The pathogenesis of gout. , 1962, Archives of internal medicine.

[37]  D. Levinson,et al.  Origin and extrarenal elimination of uric acid in man. , 1975, Nephron.

[38]  T. Paton,et al.  Efficacy and safety of desensitization to allopurinol following cutaneous reactions. , 2001, Arthritis and rheumatism.

[39]  G. Reaven,et al.  Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.

[40]  H. Schumacher,et al.  Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? , 2001, The Journal of rheumatology.

[41]  I. Fox,et al.  Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. , 1982, The New England journal of medicine.

[42]  R. Terkeltaub.  Clinical practice. Gout. , 2003, The New England journal of medicine.

[43]  A. Fam.  Should patients with interval gout be treated with urate lowering drugs? , 1995, The Journal of rheumatology.

[44]  K. Liang,et al.  Incidence and risk factors for gout in white men. , 1991, JAMA.

[45]  S. Preston,et al.  Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. , 1988, Arthritis and rheumatism.

[46]  R. Bigazzi,et al.  Effect of insulin on renal sodium and uric acid handling in essential hypertension. , 1996, American journal of hypertension.

[47]  R. Terkeltaub.  Gout and mechanisms of crystal-induced inflammation. , 1993, Current opinion in rheumatology.

[48]  J. Scott,et al.  Withdrawal of allopurinol in patients with gout. , 1974, Advances in experimental medicine and biology.

[49]  Roy Porter,et al.  Gout: The Patrician Malady , 1999 .

[50]  Hirotaka Matsuo,et al.  Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.

[51]  C. Jankowski,et al.  Elevation of serum uric acid as a clue to alcohol abuse. , 1981, Archives of internal medicine.

[52]  Charles T. Taylor,et al.  Corticotropin for Acute Management of Gout , 2001, The Annals of pharmacotherapy.

[53]  R. Wortmann.  Gout and hyperuricemia. , 2002, Current opinion in rheumatology.

[54]  W. Bilker,et al.  Quality of care indicators for gout management. , 2004, Arthritis and rheumatism.

[55]  M. Abel,et al.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.

[56]  Robert G. Godfrey,et al.  Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.

[57]  Elizabeth W Karlson,et al.  Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.

[58]  Ramsay Le,et al.  Predicting acute gout in diuretic-treated hypertensive patients. , 1989 .

[59]  P. Chou,et al.  Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. , 2000, The Journal of rheumatology.